Dry Eye Disease Therapeutics Pipeline Analysis - Clinical Trials & Results and Other Developments

Growth in the pipeline of dry eye disease therapeutics is anticipated over next few years on account of increasing incidences of people being diagnosed with diabetes and deficiency of vitamins such as A and B, which is majorly caused due to change in dietary intake and unhealthy lifestyle. This in turn leads to increase in risk of ocular infections and other bothersome symptoms such as visual disturbance, ocular discomfort and fatigue, in people. To overcome these problems, increasing number of companies are engaged in the process of developing drugs and devices that would assist in curing the disease. On the back of this, growth in the therapeutics pipeline of dry eye disease is anticipated. Additionally, increase in healthcare awareness and knowledge related to the various problem caused by environmental factors such as pollution, are also contributing to the growth of the pipeline.

Explore Report at: https://www.psmarketresearch.com/market-analysis/dry-eye-disease-therapeutics-pipeline-analysis

Dry eye disease usually occurs when eyes do not produce tears or the same is done in inconsistent proportion, due to which eyes lack moisture. The dry eye disease is also associated with inflammation in eye which can cause pain, scar on cornea, ulcer and sometimes, permanent loss of vision, due to which a person is unable to read properly and perform the daily tasks. The dry eye disease is also known as, keratoconjunctivitis sicca, dysfunctional tear disease, lacrimal keratoconjunctivitis, evaporative tear deficiency, LASIK-induced neurotrophic epitheliopathy and aqueous tear deficiency. The dry eye disease can be broadly classified into - aqueous tear-deficient dry eye and evaporative dry eye. The aqueous tear-deficient dry eye is a condition in which the lacrimal glands are unable to produce tears; whereas, evaporative dry eye problem occurs due to inflammation of meibomian glands.

Request for table of Content at: https://www.psmarketresearch.com/market-analysis/dry-eye-disease-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of dry eye disease therapeutics include, Parion Sciences, Inc., Allergan Plc, Genentech, Inc., Kissei Pharmaceutical Co., Ltd., ReGenTree, LLC, Cell Cure Neurosciences Ltd., Regenerative Patch Technologies, LLC, Topivert Pharma Ltd.

Idiopathic Pulmonary Fibrosis Pipeline Analysis, 2016 - Clinical Trials & Results, Collaboration and Other Developments

The study analyzed that the IPF pipeline comprised of 97 therapeutic candidates, of which 15 are in Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. Various drugs are being developed as novel and promising therapeutics for the treatment of IPF.

Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market

As per the findings of research, it was found that around 9% IPF candidate target chemokine, 7% target integrin and 6% of the product candidates target G-protein couple receptor. Other targets comprising 78% of candidates of IPF pipeline include, but not limited to, autotaxin, connective tissue growth factor-associated, fibroblast growth factor, lysyl-oxidase like protein 2 and tissue growth factor beta. Around 55% pipeline therapeutic candidates of IPF are being developed to be administered by oral route, 20% by inhalation route, 12% by intravenous route and 8% by subcutaneous route.

Browse Report Sample at: https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market/report-sample

U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted ODD to more than 10 drugs. As per the FDA, its Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. Tipelukast, also known as MN-001, is under Phase II stage of development by MediciNova, Inc. for the treatment of IPF. The drug was granted ODD for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if it is approved for IPF. Some of the key players developing drugs candidates for the treatment of IPF are Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Global Blood Therapeutics, Inc., Asahi Kasei Corporation, Beijing Tide Pharmaceutical Co., Limited, FibroGen, Inc., Chong Kun Dang Pharmaceutical Corp., Galapagos NV, Kadmon Holdings, Inc., MediciNova, Inc., and Promedior, Inc.

Cystic Fibrosis Therapeutics Pipeline Analysis, 2017 - Patent, Designation and Other Developments

Increasing prevalence of cystic fibrosis being witnessed mostly in Europe and the U.S. due to lack of awareness among people towards genetic diseases. In addition, some other factors contributing to the increasing occurrence of cystic fibrosis disease include smoking during pregnancy, hereditary disorder, and premature mortality of infants. The therapeutic pipeline of this particular disease is expected to grow in the future on account of major pharmaceutical companies betting involved in research & development of personalized medicines for the treatment of cystic fibrosis. In addition, various awareness programs and seminar on Cystic fibrosis are also being organized by the government, so as to make the people aware about the disease, its effects, and the possible treatments. Cystic fibrosis is the genetic disorder, which mainly affects the lungs. It is caused due to mutation in CFTR (cystic fibrosis transmembrane conductance regulator) gene. According to Center for Disease Control and Prevention, more than 30,000 people in the U.S. are infected with cystic fibrosis, while ratio of the same in newborn babies in Europe was recorded to be around one out of every 2,000 newborn babies.

Explore Report at: https://www.psmarketresearch.com/market-analysis/cystic-fibrosis-therapeutics-pipeline-analysis

Cystic fibrosis is an autosomal recessive disorder, which affects the digestive, respiratory & the reproductive system of the body. Cystic fibrosis involves the production of thick mucus in the lungs and leads to fatal infection. Mucus, a slippery material used to protect respiratory as well as digestive system, becomes abnormally thick in case of cystic fibrosis and causes damage to the lungs. The patients suffering from cystic fibrosis usually face the problem of indigestion. Major symptoms associated with cystic fibrosis or abdominal distention are loss of appetite, difficulty in breathing, gastrointestinal bleeding, persistent coughing, weight loss, bulky stool, excessive sweating, etc.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/cystic-fibrosis-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of Crohn’s disease therapeutic include Galapagos NV, Prometic Biosciences, ProQR therapeutics, Verona pharmaceuticals, Proteostasis therapeutics, Pfizer Inc., Amgen Inc., Novartis AG, Gilead sciences etc.

Anal Cancer Therapeutics Pipeline Analysis 2017 - Collaboration, and Other Developments

Anal cancer therapeutic pipeline analysis is expected to increase owing to increasing incidence globally, majorly in older adults. Major factors driving towards the pipeline growth for anal cancer include growing rate of sexually transmitted diseases and aging population. Additionally, increasing awareness regarding health issues among people is another major factor fueling the pipeline growth for anal cancer. According to American Cancer Society, the prevalence of anal cancer has increased with increasing older population. Around 8,200 new cases for anal cancer are estimated to be diagnosed with in 2017, in the U.S., out of which 5,250 cases are estimated to be present in women and 2,950 are estimated to be present in men. The disease affecting females more commonly as compared to the males.

Explore Report at: https://www.psmarketresearch.com/market-analysis/anal-cancer-therapeutics-pipeline-analysis

Anal cancer is rare type of cancer which develops tumor in the anus as a result of abnormal and uncontrolled growth of cells. It is very much different from the common colon or rectal cancers. It is more prevalent among people with a weak immune system and in women and men who receive undergo intercourse. The symptoms of anal cancer include rectal bleeding, lumps around anus, pain and mucus discharge or jelly-like discharge from anus. Women can also experience vaginal dryness and lower back pain. The risk factors associated with anal cancer are human papilloma virus infection, weakened immune system, increasing age, smoking and anal lesions. It can be diagnosed by rectal examination, biopsy, CT scan, MRI scan and ultrasound scan. Anal cancer can be treated by surgery, resection, abdominoperineal resection, chemotherapy and radiotherapy.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/anal-cancer-therapeutics-pipeline-analysis/toc-sample

Some of the key having a pipeline of anal cancer therapeutics include Advaxis, Inc., Amgen Inc., Atara Biotherapeutics Inc, Bayer AG, Cell Medica Ltd., Eli Lilly and Company, Genticel S.A., ISA Pharmaceuticals B.V., Merck & Co Inc, Millennium Pharmaceuticals Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., Oryx GmbH & Co. KG, PDS Biotechnology Corporation, Sun Pharma Advanced Research Company Ltd., Taiwan Liposome Company, Ltd.

Atopic Dermatitis Pipeline Analysis 2017 - Clinical Trials & Results, Collaboration, and Other Developments

The pipeline for atopic dermatitis therapeutic is expected to witness significant growth in the future due to rising prevalence of the disease and food allergies, which is expected to impact around 20.0% of the global population in the developed countries, according to a research done by Nutrition and Health Department, Nestle Research Centre, in 2015. Many generic drugs are already being given, but with the introduction of biologics, particularly interleukin (IL) inhibitors, is expected to be an effective future strategy for the drug manufacturers. Currently, the physicians have no other pharmacological options, which leads to treatment failure and intolerability to cyclosporine can occur when physicians prescribe off-label therapies.

Explore Report at: https://www.psmarketresearch.com/market-analysis/atopic-dermatitis-pipeline-analysis

Atopic dermatitis is a chronic inflammatory skin disease, associated with hyperactivity to environmental triggers. It has been concluded from the various clinical findings of atopic dermatitis that pruritus, facial and extensor eczema in infants and children, flexural eczema in adults and chronicity of the dermatitis in many immunologic and inflammatory pathways are activated and complex interaction among susceptibility genes occurs which led to defect in skin function, systemic and local immune responses. It also gives rise to asthma, food allergy and allergic rhinitis, which is characterized by elevated serum IgE levels and peripheral eosinophilia. There are two forms of atopic dermatitis. Extrinsic atopic dermatitis, which includes expression of skin homing receptor, cutaneous lymphocyte associated antigen by memory T cells produce Th2 cytokines. IL-13 and IL-4 are the isotypes which induce IgE synthesis and IL-5 and play an important role in eosinophil development. The T cells associated with cutaneous lymphocyte associated antigen produce abnormally low level of IFN-γ which inhibit the Th2 cell function. In intrinsic atopic dermatitis, IL-13 and IL-4 production is less.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/atopic-dermatitis-pipeline-analysis/toc-sample

In June 2016, Regeneron Pharmaceuticals, Inc. collaborated with Sanofi to produce Dupilumab, was used in the treatment along with topical corticosteroids, alone in long term phase III trials. Leo Pharma collaborated with AstraZeneca plc and acquired the global license for tralokinumab in skin diseases and exclusive license for brodalumab in Europe.

Some of the key players having a pipeline of atopic dermatitis therapeutics include LEO Pharma, Mylan Laboratories Limited, Valeant Pharmaceuticals International, Inc., Bayer AG and Encore Dermatology, Inc., Allergan, Inc., Chester Valley Pharmaceuticals, Inc., Eisai, Inc., Dermik Laboratories, Inc., Genentech, Inc., Amgen, Inc. etc.

Venous Thromboembolism Therapeutics Pipeline Analysis 2017 - Patent, Designation, Collaboration, and Other Developments

The venous thromboembolism therapeutics pipeline is expected to witness considerable growth in the coming year due to the development of novel oral anticoagulants as a reasonable and established treatment option. The regulatory bodies are supporting the drug development process through different types of designations and funding. The pipeline is being driven by different factors such as increasing awareness regarding the venous thromboembolism therapeutics pipeline, high demand for safe, effective and affordable medications, technological advancements and increasing prevalence of the venous thromboembolism.

Explore Report at: https://www.psmarketresearch.com/market-analysis/venous-thromboembolism-therapeutics-pipeline-analysis

According to American Heart Association, Venous thromboembolism (VTE) collectively develops as a combination of deep vein thrombosis (DVT) and pulmonary embolism (PE), two life-threatening conditions. Venous thromboembolism is a common and preventable disease in which the clot formation occurs in the vein associated with Venous thromboembolism. In deep vein thrombosis, a clot formed in a deep vein, usually in the leg. Pulmonary embolism is a deep vein thrombosis clot that breaks free from a vein wall, travels to the lungs and blocks some or all of the blood supply. Blood clots in the thigh are more likely to break off and travel to the lungs than the clots in lower leg or other parts of the body.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/venous-thromboembolism-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of venous thromboembolism therapeutics include Bristol-Myers Squibb Company, Pfizer, Inc., Sanofi-Aventis, Daiichi Sankyo Co. Ltd., Astellas Pharma Inc. and Johnson & Johnson.